Biocracked
Longevity Metabolism Peptides Research Supplements Trending: supplements clinical trial longevity nad+ nootropics
Approach: the human outcome. Palette: natural. A tight, low-angle shot of an elderly person's hands gripping a smooth wooden cane at the top of a sunlit garden path. The hands are weathered and slightly tremulous, with visible veins and thin, spotted skin. Behind them, the blurred figure of a seated older man in a cardigan is just recognizable, with his face out of frame. Warm late-morning daylight comes from the side and picks out the grain of the wood and the texture of the skin. The background is soft green foliage and a gravel path in shallow depth of field. The tones are plant greens, honeyed wood and natural skin. A single fresh leaf in vivid electric green sits in the lower foreground. The mood is quiet, honest and reflective, and it suggests fragility without drama.
Longevity

Lansia Lemah Duwe NAD+ Darah Sing Luwih Endhek. Apa Artine Kanggo NMN/NR

Helix Ward · · 3 min read
#aging #nmn #nad+ #nicotinamide riboside #geroscience #frailty #biomarkers

A study anyar ing GeroScience nglaporake manawa wong tuwa sing ngalami frail nduwe kadar NAD+ ing darah sing luwih endhek. Gampang banget kanggo narik kesimpulan "booster NAD+ bisa nyegah frail", nanging data sing ana ora ndhukung interpretasi kaya ngono. Ing ngisor iki apa sing ditemokake studi, keterbatasané, lan apa maknane kanggo sampeyan sing lagi mikir‑mikir babagan NMN utawa NR.

Apa sing diteliti peneliti

Shida lan kancané nitisik 529 warga komunitas umur 65 taun utawa luwih saka gelombang 2025 Itabashi Longitudinal Study on Aging ing Jepang. Sekitar 54 % saka peserta iku wanita. Dhèwèké ngukur NAD+ ing whole‑blood lan ngira‑ira frail nganggo kriteria versi anyar saka Japanese Cardiovascular Health Study.

Mung 32 peserta (6,0 %) sing nyukupi kriteria frail. Kelompok cilik iki dadi basis kanggo kabeh analisis sabanjure.

Angka utama

  • Median NAD+ whole‑blood: 24,0 µmol/L ing peserta frail vs 25,0 µmol/L ing non‑frail (P = 0,007).
  • Sawise diatur karo umur, jinis kelamin, lan wektu puasa, saben kenaikan 1 µmol/L NAD+ ana hubungane karo odds frail sing luwih murah (OR = 0,871; 95 % CI = 0,780‑0,970) – kira‑kira 13 % odds luwih endhek saben unit.
  • Analisis spline ora nemokake bukti non‑linearitas sing cetha, mula hubungane katon meh linear ing rentang sing dipelajari.
  • Regresi Firth penalised‑likelihood, sing cocok kanggo jumlah kejadian cilik lan luwih akeh kovariat, ngasilake asil sing padha (OR = 0,880; 95 % CI = 0,782‑0,986).

Kendala: hematokrit

Nalika penulis nambahake penyesuaian kanggo hematokrit (persentase volume darah sing kebak sel getih abang), asosiasi kasebut melemah. Odds ratio mudhun dadi 0,911 lan interval kapercayan (0,800‑1,034) saiki nyakup angka 1, tegesé ora ana asosiasi sing signifikan.

Iki selaras karo penjelasan alternatif sing masuk akal: NAD+ ing whole‑blood kuwat dipengaruhi dening sel getih abang, mula bisa mung nglambangaké komposisi sel darah (kayata anemia), ora nuduhaké status NAD+ ing otot, otak, utawa jaringan liya sing luwih relevan.

Kenapa iki ora mbuktèkaké “booster NAD+” nyegah frail

  1. Studi cross‑sectional. NAD+ lan frail diukur ing wektu sing padha, mulane ora bisa nemtokaké sapa sing dadi sabab lan sapa sing dadi akibat.
  2. Beda sing cilik. Selisih median mung 1 µmol/L (24 vs 25). Sanajan statistiké signifikan amarga sampel gedhé, beda iki adoh saka nilai klinis sing bisa diprediksi risiko frail individu.
  3. Kelompok frail cilik. Mung 32 kasus ndadékaké estimasi ora presisi; interval kapercayan sing amba nuduhaké iki.
  4. Whole‑blood dudu otot. Frail kaiket karo otot, mobilitas, energi, lan massa awak. NAD+ sing diukur ing darah mung proksi sing adoh saka apa sing kedaden ing otot rangka utawa sistem saraf.
  5. Asosiasi ora ateges intervensi. Sanajan NAD+ sing endhek dadi faktor kausal, ora ateges nambahake prekursor bakal mbalikaké frail. Pitakon utama yaiku apa prekursor bisa tekan jaringan sing dibutuhake.

Apa sing wis dingerteni babagan prekursor NAD+

  • Nambah NAD+ ing darah wis kabukten. Uji klinis manungsa karo NR lan NMN terus-terusan nuduhaké kenaikan kadar NAD+ utawa metabolité ing aliran darah.
  • Manfaat fungsional ora konsisten. Sawetara uji cilik nyatakake owah‑owahan modest kaya sensitivitas insulin ing otot utawa peningkatan kinerja fisik. Nanging, uji liya ora nemokake efek signifikan ing komposisi awak utawa fungsi mitokondria. Sampel biasané cilik lan periode pendek, lan populasié béda‑bèda.
  • Durung ana uji klinis sing nuduhaké prekursor NAD+ nyegah utawa mbalikaké frail klinis. Studi Itabashi ora ngowahi iki.

Takeaway praktis

  1. Aja nganggep artikel iki minangka alesan kanggo miwiti suplemen. Iki mung observasi sing ngasilaké hipotesis, dudu bukti manfaat.
  2. Waspada karo tes NAD+ ing darah konsumen. Level whole‑blood gampang keganggu dening komposisi sel getih, dadi interpretasié kudu ati‑ati.
  3. Fokus ing faktor frail sing wis kabukten. Latihan tahan (resistance training), asupan protein sing cukup, ngatasi anemia lan kondisi medis liya, lan review obat‑obatan duwé bukti sing luwih kuat tinimbang prekursor NAD+ apa wae.
  4. Yen sampeyan kepengin nyoba NMN utawa NR, diskusikaké dhisik karo dhokter, apamaneh yen sampeyan lagi ngonsumsi obat utawa nduwèni kondisi kronis utawa riwayat kanker. Pilih produk sing wis diverifikasi pihak katelu, lan elinga yèn status regulasi NMN minangka suplemen wis owah ing pasar-pasar tartamtu.
  5. Tunggu studi sing luwih apik. Langkah sabanjure sing migunani yaiku kohort longitudinal sing ngawasi NAD+ saka wektu ke wektu, ukuran spesifik jaringan, lan uji randomised kanthi endpoint frail fungsional.

Ringkesan

Studi iki nambahaké titik data sing modest nanging dilaporaké kanthi teliti: ing kohort Jepang, wong tuwa sing frail nduwe NAD+ whole‑blood sing sithik luwih endhek. Sinyal iki mudhun sawise diétangi volume sel getih abang, kelompok frail cilik, lan desain studi ora bisa netepaké sebab‑akibat. Iki ndhukung riset luwih lanjut babagan metabolisme NAD+ ing proses penuaan, nanging ora nuduhaké yèn booster NAD+ bisa nglindhungi saka frail.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

Share XFacebookLinkedInRedditWhatsApp
HW

Written by

Helix Ward

Helix Ward writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 4, conceptual metaphor, in palette D, bold color field. A single AA-style cylindrical battery, shown as a real physical object with a matte metal casing, stands upright at the center of a saturated tomato-red seamless paper backdrop. Its top half is bright and glossy, while the lower half is scuffed and dull. A thin, crisp line of electric green liquid light fills the clear gauge window along its side, stopping about three-quarters of the way up. Three smaller, identical dead batteries lie tipped over in the foreground, slightly out of focus, to suggest the rival compounds. The camera sits at a low three-quarter angle with a shallow depth of field. A hard, warm key light from the upper left casts a sharp, long shadow across the red surface. The mood is punchy and skeptical: one cell charged, the others spent.
supplements

NMN vs NR vs NADH: Siji Nambah Ketahanan, Ora Ana Sing Bisa Ngatasi Kelelahan

BY NOVA CHEN ·

Analisis jaringan meta anyar sing nyakup 27 studi lan 1.599 wong diwasa mbandhingaké NMN, NR, NADH, lan nikotinamida. Hasilé ora cocog karo janji pemasaran suplemen. NMN nuduhaké peningkatan daya tahan sing gumantung dosis (SMD ≈ 1,02 ing dosis dhuwur). NADH luwih apik kanggo kognisi, nanging mung ing kelompok sing duwe gangguan kognitif lan asilé sensitif marang sawetara studi. Kejutané, ora ana prekursor sing sacara signifikan ningkataké rasa lelah utawa kualitas turu. Artikel iki njelasaké cara peringkat diévaluasi, watesane, lan sapa sing kudu utawa ora kudu nyoba suplemen iki.
Approach: conceptual metaphor. Palette: bold color field. Subject: two identical brushed-steel analog pressure gauges side by side on a saturated mustard-yellow seamless backdrop, shot straight-on at eye level with a 85mm lens. The left gauge's needle swings down toward the low end, the right gauge's needle swings up into the high end, so they point in opposite directions. The dials are blank, with only unlabeled tick marks. A tiny electric green glass indicator lamp glows on the left gauge's rim. Lighting is a large softbox from the upper left, giving crisp highlights on the chrome bezels and short, clean shadows on the yellow surface. Shallow depth of field softens the background edges. Mood: playful, precise and tense, a visual argument between two opposing results.
longevity

NR Ngloworake Umur Epigenetik Otot, HIIT Nglawanake

BY HELIX WARD ·

NR lan HIIT loro‑loro kerep dipromosekaké minangka cara kanggo njaga otot tetep enom, nanging artikel anyar ing *Aging Cell* nemokaké yèn loro‑loro iki narik jam epigenetik menyang arah sing bertentangan. Lima wulan suplemen nicotinamide riboside (NR) ana hubungane karo pelambatan percepatan umur epigenetik otot, utamané ing jam PCHannum, MEAT, lan DunedinPACE. HIIT malah ngasilaké pola kebalik, nambah kecepatan penuaan ing jam DunedinPACE. Hubungan iki bisa uga medharake peran mitokondria, amarga owah‑owahan kandungan mitokondria otot korélasi karo owah‑owahan percepatan umur adhedhasar MEAT.
Approach: Macro science, with a Bold color field palette. Extreme close-up microscopy-style image of a single microglial cell with fine, branching processes, rendered with the real texture of fluorescence-stained tissue: translucent, slightly granular cell body, delicate ramified arms reaching across the frame. Shot from straight overhead through a microscope objective with shallow depth of field, so the outer branches soften into blur. The cell is a luminous, warm ivory-white with a few small electric green (#00e676) points of light along its branches. Behind it is a saturated, even magenta backdrop with subtle tissue grain. Lighting is crisp and backlit, with gentle glow around the edges and no harsh shadows. The mood is curious and precise, with a quiet sense of renewal. No text or labels.
longevity

Studi Tikus: NR Ngganti Sel Otak Sing Penuaan Dadi Kondisi Luwih Enom

BY NOVA CHEN ·

Ing studi GeroScience paling anyar, tikus umur 22 wulan sing diwènèhi nicotinamide riboside (NR) sajrone wolung minggu nuduhaké asil memori lan bangunan sarang sing luwih apik, sarta sel imun otaké dadi luwih mirip sel tikus enom. Iki mung studi ing tikus, ora ateges manfaaté padha kanggo manungsa. Dosae 400 mg/kg adoh banget saka dosis sing diombé wong, lan artikel iki mung nyebutaké tikus jantan. Ing ngisor iki apa sing owah ing mikroglia, watesan studi, lan apa tegese temuan iki kanggo pangguna NR.
**Approach: Human outcome. Palette: warm (B).** Extreme close-up, slightly high angle, of a woman's scalp parting in her 40s. Dense, glossy chestnut-brown hair is split by a fine comb. Short new hairs rise from the visible scalp skin, and a few strands catch the light. Faces and identity are out of frame. Low golden-hour window light enters from camera left and rim-lights the strands in honey and copper. Shadows stay warm brown, with no blue cast. The shallow depth of field blurs the background hair into soft amber bokeh. A thin steel trichoscopy probe tip sits at the edge of the frame, and a tiny electric green LED glints on its housing as the only accent. The mood is hopeful but scrutinizing, like a clinical check-up with a cautious eye.
supplements

NMN Nambah Kerapatan Rambut 57 % ing Uji Coba Manungsa—Ana Kecualian Gedhe

BY NOVA CHEN ·

NMN, suplemen sing nambah NAD+ lan dadi favorit para penggemar umur panjang, saiki kaping pisan dipriksani efeké marang pertumbuhan rambut manungsa. Ing uji pilot 12 minggu sing kalebu 15 wanita umur 40–50 taun, kerapatan rambut ing fase anagen mundhak saka 55,9 dadi 87,7 rambut/cm², déné diameter rambut nambah saka 75,3 dadi 78,8 µm. Para peserta uga nglaporake peningkatan kilau, elastisitas, lan volume rambut. Senadyan mangkono, ora ana grup plasebo, ukuran sampel cilik, lan penulis kagandheng karo pemasok NMN. Ing ngisor iki angka‑angka sing ditampilaké, apa sing ora ditampilaké, lan sapa sing kudu ngenteni.

This page is available in

English العربيةবাংলাČeštinaDeutschEspañolفارسیFrançaisHausaहिन्दीHrvatskiBahasa IndonesiaItaliano日本語Basa Jawa한국어NederlandsਪੰਜਾਬੀPolskiPortuguêsRomânăРусскийSrpskiTürkçeУкраїнськаTiếng Việt中文